SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on
Their Investment in MiMedx Group, Inc. of Class Action Lawsuit and Upcoming
Deadline -- MDXG
NEW YORK, Sept. 27, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford
Dahlstrom & Gross LLP has filed a class action lawsuit against MiMedx Group,
Inc. ("MiMedx" or the "Company") (Nasdaq:MDXG) and certain of its officers.
The class action, filed in United States District Court, Southern District of
New York, and docketed under 13-CIV-6328, is on behalf of a class consisting
of all persons or entities who purchased or otherwise acquired securities of
MiMedx between October 26, 2011 and September 4, 2013 both dates inclusive
(the "Class Period"). This class action seeks to recover damages as a result
of alleged violations of the federal securities laws pursuant to Sections
10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5
If you are a shareholder who purchased MiMedx securities during the Class
Period, you have until November 8, 2013 to ask the Court to appoint you as
Lead Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
email@example.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237.
Those who inquire by e-mail are encouraged to include their mailing address,
telephone number, and number of shares purchased.
MiMedx is a medical device company. The Company is focused on biomaterials for
soft tissue repair, such as tendons, ligaments, and cartilage, as well as
other biomaterial based products for other medical applications.
The Complaint alleges that throughout the Class Period, Defendants made false
and/or misleading statements, as well as failed to disclose material adverse
facts about the Company's business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to disclose
that: (1) the Company was in violation of the Public Health Service Act by
unlawfully manufacturing and marketing certain unapproved biologics products;
and (2) as a result of the foregoing, the Company's statements were materially
false and misleading at all relevant times.
On September 4, 2013, the Food and Drug Administration ("FDA") posted on its
website an "Untitled Letter" sent to MiMedx on August 28, 2013, which stated
that MiMedx's Surgical Biologics unit violated the Public Health Service Act
by unlawfully manufacturing and marketing drugs at one of its plants, thereby
market's unapproved biologics products. On this news, MiMedx securities
declined $2.21 per share or more than 36%, to close at $3.85 per share on
September 4, 2013.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT: Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Press spacebar to pause and continue. Press esc to stop.